- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02461186
Arterolane-PQP Versus DHA-PQP in Uncomplicated Falciparum Malaria in Eastern Myanmar
An Open-label Randomized Trial to Assess the Therapeutic Efficacy of Arterolane-piperaquine Versus Dihydroartemisinin-piperaquine for the Treatment of Uncomplicated Falciparum Malaria in Eastern Myanmar, an Area of Emerging Artemisinin-resistant Falciparum Malaria
Emerging resistance to artemisinins and their partner drugs severely threatens the treatment of falciparum malaria in Myanmar with artemisinin combination therapies. To inform drug policy, it is crucial to evaluate alternative antimalarial treatments.
The investigators here propose a randomized clinical trial comparing parasite clearance parameters and efficacy of 3 days arterolane-piperaquine with standard treatment with 3 days dihydroartemisinin (DHA)-piperaquine in adult patients with uncomplicated falciparum malaria in Myanmar stratified for the presence of "K13" mutation in the infecting parasite strains.
Study Overview
Status
Detailed Description
Primary Objective:
- To assess the parasite clearance half-life of arterolane-piperaquine compared to DHA-piperaquine in patients with artemisinin resistant uncomplicated falciparum malaria, defined by presence of the "K13" mutations in the infecting parasite strain.
Secondary Objectives :
- To assess the therapeutic efficacy of arterolane-piperaquine and DHA-piperaquine for the treatment of uncomplicated falciparum malaria or mixed infection (P.falciparum (PF) + a non-falciparum species) at Day 42, stratified by presence of artemisinin resistance in the infecting parasite strain.
- To assess the frequency of adverse events and serious adverse events of arterolane-piperaquine compared to DHA-piperaquine.
- To assess other efficacy parameters related to parasite clearance and parasite cure rate as well as the gametocyte carriage.
- To obtain pharmacokinetic (PK) and pharmacokinetic/pharmacodynamics (PK/PD) data on arterolane-piperaquine and DHA-piperaquine.
Study Type
Phase
- Phase 2
- Phase 3
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Male or female aged ≥ 18 year old
- Symptomatic malaria infection, i.e. history of fever or presence of fever >37.5°c (tympanic) within the last 24 hours.
- Microscopic confirmation of asexual stages of P.falciparum (may be mixed with non-falciparum species) with a parasitaemia >10,000 parasites/µL
- Able to take oral medication
- Willingness and ability of patients to comply with the study protocol for the duration of the study
- Written informed consent given to participate in the trial
Exclusion Criteria:
- Pregnancy or lactation (urine test for β HCG to be performed on any woman of child bearing age 18 to 45 year old)
- P.falciparum asexual stage parasitaemia greater than or equal to 4% red blood cells (175,000/µL).
Signs or symptoms indicative of severe malaria:
- Impaired consciousness
- Severe anaemia (Hct<15%)
- Bleeding disorder -evidenced by epistaxis, bleeding gums, frank haematuria, bleeding from venipuncture sites
- Respiratory distress
- Severe jaundice
- Have taken a full course DHA-piperaquine, artemether-lumefantrin or other antimalarial treatment in the previous 42 days
- Known hypersensitivity to artemisinins or to piperaquine - defined as history of erythroderma/other severe cutaneous reaction or angioedema
- History of splenectomy
History of taking medicinal products that are known to prolong the QTc interval, including:
- Antiarrhythmics (e.g. amiodarone, disopyramide, dofetilide, ibutilide, procainamide, quinidine, hydroquinidine, sotalol).
- Neuroleptics (e.g. phenothiazines, sertindole, sultopride, chlorpromazine, haloperidol, mesoridazine, pimozide, or thioridazine), antidepressive agents.
Certain antimicrobial agents, including agents of the following classes:
- macrolides (e.g. erythromycin, clarithromycin),
- fluoroquinolones (e.g. moxifloxacin, sparfloxacin),
- imidazole and triazole antifungal agent,
- pentamidine and saquinavir.
- The non-sedating antihistamines terfenadine, astemizole, mizolastine.
- Other drugs: cisapride, droperidol, domperidone, bepridil, diphemanil, probucol, levomethadyl, methadone, vinca alkaloids, arsenic trioxide.
- History of taking any drug which is known to be metabolised by the cytochrome enzyme CYP2D6 including flecainide, metoprol, imipramine, amitriptyline, clomipramine.
- Family history of sudden unexplained death, or personal or family history of predisposing cardiac conditions for arrhythmia/QT prolongation (including congenital long QT syndrome, arrhythmia, QTc interval greater than 450 milliseconds with either Bazett or Fridericia correction).
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Arterolane maleate-piperaquine phosphate (Synriam)
|
|
Experimental: Dihydroartemisinin-piperaquine phosphate (Duocotexin)
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Peripheral blood parasite half-life
Time Frame: 2 years
|
Peripheral blood parasite half-life of the linear portion of the natural logarithm parasite clearance curve in patients with parasitaemia at inclusion >10,000 parasites/µL
|
2 years
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
42 day PCR corrected adequate clinical and parasitological response (ACPR)
Time Frame: 42 days
|
42 days
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Arjen M Dondorp, MD, Mahidol Oxfrod Tropical Medicine Research Unit
Study record dates
Study Major Dates
Study Start
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- BAKMAL1501
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Uncomplicated Falciparum Malaria
-
Syamsudin Abdillah,Ph.D, Pharm DCipto Mangunkusumo Hospital; PT Natura Nuswantara NirmalaCompletedInfections | Malaria | Malaria, Vivax | Uncomplicated Malaria | Malaria,Falciparum | Uncomplicated Plasmodium FalciparumIndonesia
-
Medical University of ViennaInternational Centre for Diarrhoeal Disease Research, Bangladesh; Armed Forces...CompletedAzithromycin Combination Therapy for the Treatment of Uncomplicated Falciparum Malaria in BangladeshUncomplicated Falciparum MalariaBangladesh
-
Medecins Sans Frontieres, NetherlandsUniversity of Oxford; Mahidol University; Disease Control, Department of Health...UnknownUncomplicated Falciparum MalariaMyanmar
-
Johns Hopkins Bloomberg School of Public HealthTropical Diseases Research CentreActive, not recruitingUncomplicated Falciparum MalariaZambia
-
University of OxfordMahidol University; Medicines for Malaria VentureWithdrawnUncomplicated Falciparum MalariaCambodia
-
London School of Hygiene and Tropical MedicineHealthNet TPOCompleted
-
National Institute for Medical Research, TanzaniaWorld Health Organization; Muhimbili University of Health and Allied SciencesCompletedUncomplicated Falciparum MalariaTanzania
-
Heidelberg UniversityCompletedUncomplicated Falciparum MalariaBurkina Faso
-
Novartis PharmaceuticalsRecruitingUncomplicated Plasmodium Falciparum MalariaCôte D'Ivoire, Kenya, Ghana, Uganda
-
Medicines for Malaria VentureCompletedUncomplicated Plasmodium Falciparum MalariaUganda, Benin, Burkina Faso, Congo, The Democratic Republic of the, Gabon, Mozambique, Vietnam
Clinical Trials on Arterolane maleate-piperaquine phosphate (Synriam)
-
University of OxfordMahidol Oxford Tropical Medicine Research UnitCompleted
-
Medicines for Malaria VentureCompleted
-
Novartis PharmaceuticalsMedicine for Malaria VentureTerminatedPlasmodium Falciparum MalariaAustralia
-
Medicines for Malaria VentureQ-Pharm Pty Limited; Clinical Network Services (CNS) Pty Ltd; QIMR Berghofer... and other collaboratorsCompleted
-
Ifakara Health InstituteCompletedMalaria, Falciparum | Plasmodium FalciparumTanzania
-
London School of Hygiene and Tropical MedicineCheikh Anta Diop University, SenegalCompleted
-
Papua New Guinea Institute of Medical ResearchUniversity of Melbourne; The University of Western Australia; Malaria in Pregnancy...UnknownPregnancy | Clinical Efficacy | Drug Kinetics | Infections, PlasmodiaPapua New Guinea
-
Medicines for Malaria VentureQ-Pharm Pty Limited; Clinical Network Services (CNS) Pty Ltd; QIMR Berghofer...Completed
-
Radboud University Medical CenterThe PATH Malaria Vaccine Initiative (MVI); QIMR Berghofer Medical Research...Completed
-
Radboud University Medical CenterThe PATH Malaria Vaccine Initiative (MVI); QIMR Berghofer Medical Research...CompletedTransmission | Malaria,Falciparum | Controlled Human Malaria Infection | GametocytesNetherlands